Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 18/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 18/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 15/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 15/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 10/20 | 0.58 |
| ▸ | USP2 | O75604 | 10/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.58 |
| ▸ | LMNA | P02545 | 8/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 7/20 | 0.58 |
| ▸ | TSHR | P16473 | 6/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.58 |
| ▸ | HPGD | P15428 | 5/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.58 |
| ▸ | MEN1 | O00255 | 5/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | RAF1 | P04049 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | CLK4 | Q9HAZ1 | 8/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4065080 | 0.90 | CYP1A2 (0.55) | CYP1A2CYP3A4CYP2D6CYP2C19CYP2C9 | |
| SCHEMBL4063754 | 0.85 | PDE5A (0.52) | CYP1A2CYP3A4CYP2D6CYP2C19CYP2C9 | |
| SCHEMBL4069374 | 0.85 | CLK4 (0.53) | CYP1A2CYP3A4CYP2D6CYP2C19USP2 | |
| SCHEMBL4066184 | 0.85 | FLT1 (0.56) | ALDH1A1KDM4ETP53EGFRFLT1 | |
| SCHEMBL4071318 | 0.81 | EGFR (0.52) | ALDH1A1KDM4ECLK4EGFRFLT1 | |
| SCHEMBL4068541 | 0.81 | FLT1 (0.48) | EGFRFLT1 | |
| SCHEMBL4065012 | 0.79 | TYK2 (0.66) | ALDH1A1LMNAKDM4ECLK4EGFR | |
| SCHEMBL4069817 | 0.77 | CYP1A2 (0.46) | CYP1A2CYP3A4CYP2D6CYP2C19CYP2C9 | |
| SCHEMBL4066517 | 0.77 | CLK4 (0.52) | CYP1A2CYP3A4CYP2D6CYP2C19CYP2C9 | |
| SCHEMBL4076692 | 0.76 | CYP1A2 (0.55) | CYP1A2CYP3A4CYP2D6CYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042878-A1 | THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SHERING PHARMA AG (DE) | 2009-02-12 | — | — | US | claimed |
| EP-2014663-A1 | Thieno-pyrimidyl amines as modulators of EP2 receptors | Bayer Schering Pharma AG (DE) | 2009-01-14 | — | — | EP | claimed |
| US-20090042878-A1 | THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SHERING PHARMA AG (DE) | 2009-02-12 | — | — | US | disclosed |
| US-20090042878-A1 | THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SHERING PHARMA AG (DE) | 2009-02-12 | — | — | US | disclosed |
| US-20090042878-A1 | THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SHERING PHARMA AG (DE) | 2009-02-12 | — | — | US | disclosed |
| EP-2014663-A1 | Thieno-pyrimidyl amines as modulators of EP2 receptors | Bayer Schering Pharma AG (DE) | 2009-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042878-A1 | THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR | PTGER2, PTGER1, PTGDR2 | CYP1A2 137/4885CYP3A4 601/4885CYP2D6 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.